{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:59:14Z","timestamp":1772722754645,"version":"3.50.1"},"reference-count":50,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT BACKGROUND: Autoimmune hepatitis (AIH) is a chronic liver disease, characterized by necroinflammation and autoimmune etiology. Studies evaluating the characteristics of patients with AIH are scarce in Brazil. OBJECTIVE: Our objective was to evaluate the profile of patients with AIH in a specialized center in Southern Brazil and to verify factors related to treatment response. METHODS: this was a retrospective cohort study, which analyzed demographic, epidemiological, clinical, laboratory, and histologic data. Patients with AIH diagnosed according to the criteria of the International Autoimmune Hepatitis Group (IAIHG) were included. In liver biopsies, the degree of fibrosis, histological activity, presence of hepatocyte rosettes, plasma cell infiltrates, and confluent necrosis were evaluated. In the statistical analysis, the significance level was 5%. RESULTS: Forty adults patients diagnosed with AIH were included. The evaluated population predominantly consisted of women (75.0%) and the average age at diagnosis was 44.2 years. The association with extrahepatic autoimmune diseases occurred in 20.0% of cases. Clinically, 35.0% of patients presented with acute onset hepatitis, 37.5% with cirrhosis, and 27.5% with other forms of presentation. The most common clinical manifestation was jaundice (47.5%). Thirty-five patients were treated, and of these, 97.1% used prednisone combined with azathioprine. The average treatment time was 2.7 years. Response to treatment was complete or partial in 30 (85.7%) and absent in 5 (14.3%) patients. There was no statistically significant difference when evaluating response to treatment in relation to forms of presentation, histological findings, and the presence of autoantibodies. Regarding fibrosis, regression was observed in 18.75% of the cases. CONCLUSION: Most patients with AIH were young at presentation and of female sex. The association with extrahepatic autoimmune diseases and cirrhosis at presentation was seen in a considerable proportion of patients. Treatment was effective, but there were no clinical, histological or serological parameters capable of predicting treatment response.<\/jats:p>","DOI":"10.1590\/s0004-2803.202000000-69","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T23:00:43Z","timestamp":1605913243000},"page":"361-365","source":"Crossref","is-referenced-by-count":6,"title":["EVALUATION OF PATIENTS WITH AUTOIMMUNE HEPATITIS IN A SPECIALIZED OUTPATIENT CLINIC IN SOUTHERN BRAZIL"],"prefix":"10.1590","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7928-3335","authenticated-orcid":false,"given":"Renata S","family":"FEDRIZZI","sequence":"first","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-2871","authenticated-orcid":false,"given":"Gabriela P","family":"CORAL","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2417-9765","authenticated-orcid":false,"given":"Angelo A de","family":"MATTOS","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-0199","authenticated-orcid":false,"given":"\u00c2ngelo Z de","family":"MATTOS","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-5937","authenticated-orcid":false,"given":"Cristiane V","family":"TOVO","sequence":"additional","affiliation":[{"name":"Universidade Federal de Ci\u00eancias da Sa\u00fade de Porto Alegre, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2020,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1089-3261(02)00019-3","article-title":"Autoimmune hepatitis: diagnostic criteria, subclassification, and clinical features","volume":"6","author":"McFarlane IG","year":"2002","journal-title":"Clin Liv Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez F","year":"1999","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","article-title":"Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands","volume":"49","author":"Van Gerven NMF","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1089-3261(02)00021-1","article-title":"Prevalence and epidemiology of autoimmune hepatitis","volume":"6","author":"Boberg KM","year":"2002","journal-title":"Clin Liv Dis"},{"key":"ref5","first-page":"1118","article-title":"Epidemiology of autoimmune liver disease","volume":"18","author":"Feld JJ","year":"2003","journal-title":"J Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1023\/A:1018836004279","article-title":"Immune phenotype of chronic liver disease","volume":"43","author":"Czaja AJ","year":"1998","journal-title":"Dig Dis Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2007.08.013","article-title":"Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis","volume":"48","author":"Al-Chalabi T","year":"2008","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0016-5085(92)90041-V","article-title":"HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients","volume":"103","author":"Seki T","year":"1992","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.3748\/wjg.14.4607","article-title":"Chronic liver disease in Aboriginal North Americans","volume":"14","author":"Scott JD","year":"2008","journal-title":"World J Gastroenterol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cld.2005.07.004","article-title":"Autoimmune hepatitis","volume":"9","author":"Thiele DL","year":"2005","journal-title":"Clin Liv Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-2002-35702","article-title":"Definition and classification of autoimmune hepatitis","volume":"22","author":"McFalane IG","year":"2002","journal-title":"Sem Liv Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.510300611","article-title":"Pediatric and Adult Forms of Type I Autoimmune Hepatitis in Argentina: Evidence for Differential Genetic Predisposition","volume":"30","author":"Pando M","year":"1999","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.autrev.2010.09.024","article-title":"Autoimmune hepatitis, HLA and extended haplotypes","volume":"10","author":"Oliveira LC","year":"2011","journal-title":"Autoimmun Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0168-8278(02)00182-4","article-title":"Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States","volume":"37","author":"Czaja AJ","year":"2002","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0168-8278(98)80347-4","article-title":"MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatites","volume":"28","author":"Vazquez-Garc\u0131a MN","year":"1998","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jped.2018.04.007","article-title":"Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes","volume":"95","author":"Porta G","year":"2019","journal-title":"J Pediatr"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0b013e31802dbdfc","article-title":"Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background","volume":"42","author":"Bittencourt PL","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"ref18","series-title":"Etnias e popula\u00e7\u00e3o do Rio Grande do Sul","author":"Francisco WCE","year":"2019"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases","volume":"72","author":"Mack CL","year":"2019","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune Hepatitis","volume":"354","author":"Krawitt E","year":"2006","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa P","year":"1996","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1440-1746.2006.04130.x","article-title":"Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial\/anti-M2 seropositive variant form of autoimmune hepatits","volume":"21","author":"Farias AQ","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.26666","article-title":"Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis","volume":"59","author":"Couto CA","year":"2014","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","article-title":"Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study","volume":"43","author":"Werner M","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gr\u00f8nb\u00e6k L","year":"2014","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00535-011-0421-y","article-title":"Present status of autoimmune hepatits in Japan: a nationwide survey","volume":"46","author":"Abe M","year":"2011","journal-title":"J Gastroenterol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","article-title":"Autoimmune hepatitis in the elderly: A systematic retrospective analysis of a large group of consecutive patients with definite AIH followes at tertiary referral centre","volume":"45","author":"Al-Chalabi T","year":"2006","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.50.5.713","article-title":"Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic","volume":"50","author":"Zolfino T","year":"2002","journal-title":"Gut"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2006.03104.x","article-title":"Type I autoimmune hepatitis: clinical course and autcome in na Italian multicentre study","volume":"24","author":"Floreani A","year":"2006","journal-title":"Alim Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","article-title":"Prognosis of histological cirrhosis in type 1 autoimmune hepatitis","volume":"110","author":"Roberts SK","year":"1996","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1478-3231.2005.01141.x","article-title":"Autoimmune hepatitis type 1:safety and efficacy of prolonged medical therapy","volume":"25","author":"Seela S","year":"2005","journal-title":"Liv Int"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1600-0676.2003.00810.x","article-title":"Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis","volume":"23","author":"Czaja AJ","year":"2003","journal-title":"Liv Int"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00001574-200405000-00007","article-title":"Autoimmune liver disease","volume":"20","author":"Czaja AJ","year":"2004","journal-title":"Curr Opin Gastroenterol"},{"key":"ref35","first-page":"55","article-title":"Autoimmune hepatitis - Approach to diagnosis","volume":"8","author":"Czaja AJ","year":"2006","journal-title":"Med Gen Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1572-0241.2002.05921.x","article-title":"Gender effects and synergisms with histocompatibility leukocyte antigens in type1 autoimmune hepatitis","volume":"97","author":"Czaja AJ","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","article-title":"Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly","volume":"43","author":"Czaja AJ","year":"2006","journal-title":"Hepatology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","article-title":"Factors predicting relapse and poor outcome in type I autoimmune hepatits: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy","volume":"99","author":"Verma S","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.20539","article-title":"Treatment challenges and investigational opportunities in autoimmune hepatitis","volume":"41","author":"Czaja AJ","year":"2005","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1002\/hep.21059","article-title":"Autoimmune hepatitis, from mechanisms to therapy","volume":"43","author":"Manns MP","year":"2006","journal-title":"Hepatology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the Bologna experience","volume":"50","author":"Muratori P","year":"2009","journal-title":"J Hepatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld JJ","year":"2005","journal-title":"Hepatology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1872-034X.2011.00808.x","article-title":"Acute presentation of autoimmune hepatitis: Does it exist? A published work review","volume":"41","author":"Takahashi H","year":"2011","journal-title":"Hepatol Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2002-35704","article-title":"Autoantibodies and antoantigens in autoimmune hepatitis","volume":"22","author":"Strassburg CP","year":"2002","journal-title":"Sem Liv Dis"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/gast.2001.20223","article-title":"Autoantibodies in liver disease","volume":"120","author":"Czaja AJ","year":"2001","journal-title":"Gastroenterology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"Diagnosis and treatment of hepatitis autoimmune. AASLD Practice Guideline","volume":"36","author":"Czaja AJ","year":"2002","journal-title":"Hepatology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3748\/wjg.15.578","article-title":"Hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"15","author":"Teufel A","year":"2009","journal-title":"World J Gastroenterol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.22432","article-title":"Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening","volume":"48","author":"Yeoman AD","year":"2008","journal-title":"Hepatology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-2007-979472","article-title":"Guidelines for therapy of autoimmune liver disease","volume":"27","author":"Ishibashi H","year":"2007","journal-title":"Sem Liv Dis"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80096-8","article-title":"Behavior and significance of autoantibodies in type 1 autoimmune hepatitis","volume":"30","author":"Czaja AJ","year":"1999","journal-title":"J Hepatol"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v57n4\/1678-4219-ag-s0004280320200000069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:43:27Z","timestamp":1618443807000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032020000400361&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["S0004-28032020000400361"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202000000-69","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}